<DOC>
	<DOCNO>NCT00988637</DOCNO>
	<brief_summary>This clinical trial evaluate efficacy safety Clobex® ( clobetasol propionate ) Spray 0.05 % Vectical™ ( calcitriol ) Ointment 3 µg/g four week period use one two different regimen : 1 . Vectical™ Ointment treatment , twice daily weekday ( Mon - Fri ) Clobex® Spray treatment twice daily weekend ( Sat - Sun ) 28 day 2 . Clobex® Spray morning Vectical™ Ointment even 28 day</brief_summary>
	<brief_title>Evaluate Safety/Efficacy Two Treatment Regimens Vectical™ Ointment &amp; Clobex® Spray Moderate Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Male female subject age 18 80 year inclusive Subjects Overall Disease Severity 3 ( moderate ) Subjects 3 % 10 % treatable BSA ( Body Surface Area ) exclude scalp , face , groin , axillae and/or intertriginous area For concurrent medication , type dose must stable least 3 month prior study entry expect change study . Subjects receive treatment betablockers lithium , whose dose stable l 6 month show worsen psoriasis , may include study , discretion investigator Subjects intakes 2,000 IU/day ( 50 mcg/day ) vitamin D ( tolerable upper intake level ) and/or 1,000 mg/day calcium Subjects whose psoriasis involve scalp , face , groin , axilla , and/or intertriginous area Subjects washout period topical treatment le 30 day ( Any steroid contain medication , dovonex , anthralin , tar and/or UVB treatment ) Subjects washout period systemic treatment le 12 week ( corticosteroid , biologics and/or PUVA treatment ; Examples therapy include , limited PUVA , Soriatane , Cyclosporine , Hydroxyurea , Mycophenolate mofetil , Sulfasalazine , Azathioprine , Alefacept , Efalizumab , Adalimumab , Etanercept , Infliximab , Rituximab , Methotrexate ) Subjects nonplaque psoriasis relate disease classify plaque psoriasis Subjects foresee intensive UV exposure study ( mountain sport , UV radiation , sunbathe , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>